Thrivent Financial for Lutherans
LGND icon

Thrivent Financial for Lutherans’s Ligand Pharmaceuticals LGND Stock Holding History

Thrivent Financial for Lutherans’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.62M Sell
13,138
-387
-3% -$76.6K 0.01% 1252
2025
Q4 		$2.56M Sell
13,525
-613
-4% -$118K ﹤0.01% 1311
2025
Q3 		$2.5M Sell
14,138
-49
-0.3% -$7.28K ﹤0.01% 1204
2025
Q2 		$1.61M Sell
14,187
-196
-1% -$20.9K ﹤0.01% 1491
2025
Q1 		$1.51M Sell
14,383
-726
-5% -$82.1K ﹤0.01% 1444
2024
Q4 		$1.62M Buy
15,109
+25
+0.2% +$2.83K ﹤0.01% 1594
2024
Q3 		$1.51M Buy
15,084
+329
+2% +$33.1K ﹤0.01% 1643
2024
Q2 		$1.24M Sell
14,755
-243
-2% -$19.3K ﹤0.01% 1721
2024
Q1 		$1.1M Sell
14,998
-386
-3% -$28.5K ﹤0.01% 1861
2023
Q4 		$1.1M Sell
15,384
-359
-2% -$21.2K ﹤0.01% 1783
2023
Q3 		$943K Sell
15,743
-774
-5% -$50.9K ﹤0.01% 1784
2023
Q2 		$1.19M Sell
16,517
-269
-2% -$20.2K ﹤0.01% 1685
2023
Q1 		$1.24M Buy
16,786
+323
+2% +$23K ﹤0.01% 1648
2022
Q4 		$1.1M Sell
16,463
-10,115
-38% -$658K ﹤0.01% 1668
2022
Q3 		$1.43M Buy
26,578
+23
+0.1% +$1.35K ﹤0.01% 1442
2022
Q2 		$1.48M Buy
26,555
+4,746
+22% +$269K ﹤0.01% 1435
2022
Q1 		$1.53M Buy
21,809
+8
+0% +$580 ﹤0.01% 1507
2021
Q4 		$2.1M Buy
21,801
+193
+0.9% +$17.8K ﹤0.01% 1363
2021
Q3 		$1.88M Buy
21,608
+14,521
+205% +$1.12M ﹤0.01% 1390
2021
Q2 		$580K Buy
7,087
+8
+0.1% +$665 ﹤0.01% 2131
2021
Q1 		$673K Sell
7,079
-87,948
-93% -$8.31M ﹤0.01% 2098
2020
Q4 		$5.89M Buy
95,027
+703
+0.7% +$40.1K 0.01% 804
2020
Q3 		$5.61M Sell
94,324
-2,648
-3% -$181K 0.02% 760
2020
Q2 		$6.77M Sell
96,972
-78,744
-45% -$4.99M 0.02% 645
2020
Q1 		$7.97M Sell
175,716
-671,425
-79% -$38.1M 0.03% 559
2019
Q4 		$55.1M Buy
847,141
+130,018
+18% +$8.69M 0.16% 175
2019
Q3 		$44.5M Buy
717,123
+22,008
+3% +$1.38M 0.14% 181
2019
Q2 		$49.5M Buy
695,115
+11,081
+2% +$816K 0.15% 169
2019
Q1 		$53.6M Buy
684,034
+236,502
+53% +$17.9M 0.17% 163
2018
Q4 		$37.9M Buy
447,532
+424,470
+1,841% +$45.3M 0.14% 181
2018
Q3 		$3.95M Sell
23,062
-383
-2% -$57.7K 0.01% 706
2018
Q2 		$3.03M Buy
23,445
+662
+3% +$73.9K 0.01% 762
2018
Q1 		$2.35M Buy
22,783
+1,787
+9% +$177K 0.01% 842
2017
Q4 		$1.79M Buy
20,996
+413
+2% +$35.8K 0.01% 961
2017
Q3 		$1.75M Buy
20,583
+2,213
+12% +$175K 0.01% 911
2017
Q2 		$1.39M Buy
18,370
+1,266
+7% +$88.6K 0.01% 971
2017
Q1 		$1.13M Buy
17,104
+705
+4% +$46.4K ﹤0.01% 1098
2016
Q4 		$1.04M Buy
16,399
+866
+6% +$54.6K ﹤0.01% 1128
2016
Q3 		$989K Buy
15,533
+769
+5% +$56.5K ﹤0.01% 1134
2016
Q2 		$1.1M Buy
14,764
+1,860
+14% +$138K 0.01% 1068
2016
Q1 		$862K Buy
12,904
+465
+4% +$28.3K ﹤0.01% 1131
2015
Q4 		$841K Buy
12,439
+256
+2% +$15.8K ﹤0.01% 1124
2015
Q3 		$651K Buy
12,183
+1,042
+9% +$63.2K ﹤0.01% 1100
2015
Q2 		$701K Buy
11,141
+481
+5% +$26.2K ﹤0.01% 950
2015
Q1 		$513K Hold
10,660
– – ﹤0.01% 1100
2014
Q4 		$354K Sell
10,660
-401
-4% -$13K ﹤0.01% 1297
2014
Q3 		$324K Sell
11,061
-1,122
-9% -$37.2K ﹤0.01% 1329
2014
Q2 		$473K Buy
12,183
+160
+1% +$6.49K ﹤0.01% 1151
2014
Q1 		$505K Buy
12,023
+161
+1% +$6.71K ﹤0.01% 953
2013
Q4 		$389K Buy
+11,862
New +$386K ﹤0.01% 1109

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

Thrivent Financial for Lutherans's LGND Position: Q1 2026 in Review

Thrivent Financial for Lutherans reduced its Ligand Pharmaceuticals (LGND) stake by 2.9% in Q1 2026, selling an estimated $76.6K and leaving 13,138 shares worth $2.62M. The position accounts for 0.01% of the portfolio, ranked #1252.

Thrivent Financial for Lutherans first reported a position in LGND in Q4 2013 and has held it in 50 quarters since. The position peaked at $55.1M in Q4 2019. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.

  • Thrivent Financial for Lutherans held 13,138 shares of Ligand Pharmaceuticals worth $2.62M as of Q1 2026.
  • Thrivent Financial for Lutherans sold 387 Ligand Pharmaceuticals shares in Q1 2026, an estimated $76.6K.
  • Ligand Pharmaceuticals made up 0.01% of Thrivent Financial for Lutherans's portfolio in Q1 2026, its #1252 holding.
  • Thrivent Financial for Lutherans first reported a position in Ligand Pharmaceuticals in Q4 2013 and has held it in 50 quarters since.
  • Thrivent Financial for Lutherans's Ligand Pharmaceuticals position peaked at $55.1M in Q4 2019.
  • 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.

Based on Thrivent Financial for Lutherans's 13F filing for Q1 2026, filed 1 May 2026.